🇺🇸 FDA
Patent

US 10525123

Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment

granted A61KA61K2039/5256A61K2039/545

Quick answer

US patent 10525123 (Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment) held by The Government of the United States, as represented by the Secretary of the Army expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Government of the United States, as represented by the Secretary of the Army
Grant date
Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/5256, A61K2039/545, A61K2039/57, A61K2039/575